Humira holds on for another quarter as AbbVie beats expectations

Chicago’s AbbVie (NYSE: ABBV) has reported second quarter revenues of $8.3 billion, up 19.2% on the same period last year, ahead of many analysts’ expectations.

Using Generally Accepted Accounting Principles (GAAP), the firm reported an earnings per share figure of $1.26.

The results were supported by continued strong performance for blockbuster anti-TNF therapy Humira (adalimumab), with sales increasing 10% on a reported basis, despite increasing competition from generics.